Advertisement

Topics

Eisai Inc Company Profile

16:57 EST 10th December 2018 | BioPortfolio

Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide. Our company's hhc mission symbol is derived from the letters in Florence Nightingale's signature. Following the example set by this famed health care pioneer, who devoted her life to caring for others yet never lost sight of the importance of listening to her patients, Eisai marshals its talents to explore new therapeutic approaches that address two key goals: meeting the medical needs of patients and their families, and improving their quality of life.

Location

Glenpointe Centre West500 Frank W. Burr Boulevard
Teaneck
New Jersey
07666
United States of America

Contact

Phone: 201-692-1100


News Articles [281 Associated News Articles listed on BioPortfolio]

Oncodesign Furthers Its Cooperation with Eisai, Started 12 Years Ago

Signature of a new services agreement on breast cancer with the Japanese pharmaceutical company Eisai This program's objective is to define the clinical positioning strategy of Eisai new compounds...

Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy

TOKYO, Oct 1, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expans...

Eisai commences full-scale operation of new production site

Eisai Co., Ltd. announced that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening cere...

Eisai: Results from Two Phase 3 Clinical Trials of Chronic Constipation Treatment "GOOFICE 5mg Tablet" Published in The Lancet Gastroenterology & Hepatology

TOKYO, July 9, 2018 - (JCN Newswire) - Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that results from two phas...

Chinese drug authority accepts Eisai's NDA for Perampanel to treat partial onset seizures

Eisai Co, Ltd has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai's antiepileptic drug (AED) perampanel (generic name, pro...

Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease

At the 11th Clinical Trials in Alzheimer's Disease ConferenceTOKYO, Oct 26, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of ...

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (per...

Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence

TOKYO, Nov 8, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. announced today that EA Pharma has entered into an industry-academia-g...

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Halaven [Eisai Inc.]

These highlights do not include all the information needed to use HALAVEN™ safely and effectively. See full prescribing information for HALAVEN. HALAVEN™ (eribulin mesylate) Injection For intraven...

Lusedra [Eisai, Inc]

These highlights do not include all the information needed to use LUSEDRA safely and effectively. See full prescribing information for LUSEDRA. LUSEDRA (fospropofol disodium) Injection, for intravenou...

Ontak [Eisai, Inc]

These highlights do not include all the information needed to use Ontak safely and effectively. See full prescribing information for Ontak. ONTAK (denileukin diftitox) Injection for intravenous infusi...

Hexalen [Eisai Inc.]

HEXALEN (ALTRETAMINE) CAPSULES 50 mg R Only

Targretin [Eisai Inc.]

Targretin® (bexarotene) capsules, 75 mg

PubMed Articles [0 Results]

None

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA...

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a...

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union (EU) for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of ...

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is cond...

Companies [14 Associated Companies listed on BioPortfolio]

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Inc" on BioPortfolio

We have published hundreds of Eisai Inc news stories on BioPortfolio along with dozens of Eisai Inc Clinical Trials and PubMed Articles about Eisai Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Inc Companies in our database. You can also find out about relevant Eisai Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record